TFF Pharmaceuticals, Inc. (TFFP) Stock Analysis

TFF Pharmaceuticals, Inc. (TFFP) Healthcare & Pipeline Overview

TFF Pharmaceuticals, Inc. develops inhaled dry powder drugs using its patented Thin Film Freezing (TFF) technology, targeting pulmonary diseases and conditions. Its lead candidates, TFF Voriconazole and TFF Tacrolimus, are in Phase II clinical trials, positioning the company within the competitive biotechnology sector focused on innovative drug delivery systems.

What Is the Investment Thesis for TFFP?

TFF Pharmaceuticals presents a notable research candidate within the biotechnology sector, driven by its innovative Thin Film Freezing (TFF) technology. The company's focus on inhaled dry powder drugs for pulmonary diseases addresses a significant market need. Positive Phase II clinical trial results for TFF Voriconazole and TFF Tacrolimus could serve as major catalysts, potentially leading to partnerships or acquisitions. However, the company's negative profit margin of -2894.7% and reliance on clinical trial success pose significant risks. Successful commercialization and market adoption of its products are crucial for long-term value creation. The company's relatively small market cap also introduces volatility.

Based on FMP financials and quantitative analysis

TFFP Key Highlights

TFF Pharmaceuticals is a clinical-stage biopharmaceutical company focused on inhaled dry powder drugs.

• The company's lead drug candidates, TFF Voriconazole and TFF Tacrolimus, are in Phase II clinical trials.
• TFF Pharmaceuticals' technology platform, Thin Film Freezing (TFF), offers a novel approach to drug delivery.
• The company has a negative profit margin of -2894.7%, indicating significant ongoing investment in research and development.
• TFF Pharmaceuticals has a Gross Margin of 31.5%.

Who Are TFFP's Competitors?

TFFP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TFFP's Key Strengths?

Proprietary Thin Film Freezing (TFF) technology.

• Focus on inhaled dry powder drugs.
• Lead drug candidates in Phase II clinical trials.
• Strategic collaborations with universities and other companies.

What Are TFFP's Weaknesses?

Negative profit margin.

• Reliance on clinical trial success.
• Limited commercialization experience.
• Small market capitalization.

What Could Drive TFFP Stock Higher?

Phase II clinical trial results for TFF Voriconazole Inhalation Powder (invasive pulmonary aspergillosis).

• Phase II clinical trial results for TFF Tacrolimus Inhalation Powder (lung transplant rejection prevention).
• Potential partnerships with larger pharmaceutical companies.
• Expansion into new therapeutic areas using TFF technology.

What Are the Key Risks for TFFP?

Financial-distress signal — its Altman Z-Score of -34.60 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results.
• Regulatory delays or rejection.
• Competition from other drug delivery technologies.
• Reliance on key personnel.
• Negative profit margin and need for additional funding.

What Are the Growth Opportunities for TFFP?

• Expansion into New Therapeutic Areas: TFF Pharmaceuticals has the opportunity to leverage its Thin Film Freezing (TFF) technology to develop inhaled dry powder drugs for a wider range of therapeutic areas beyond pulmonary diseases. This includes exploring applications in areas such as neurology, oncology, and infectious diseases. Success in these new areas could significantly diversify the company's product pipeline and revenue streams.
• Strategic Partnerships and Collaborations: TFF Pharmaceuticals can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborating with established players can provide access to funding, expertise, and distribution networks. The company already has existing agreements with the University of Texas at Austin, Augmenta Bioworks, Inc., and UNION therapeutics A/S. Further partnerships could enhance its capabilities and market reach.
• Advancement of Clinical Pipeline: The successful advancement of TFF Pharmaceuticals' clinical pipeline, particularly TFF Voriconazole and TFF Tacrolimus, represents a significant growth opportunity. Positive Phase II clinical trial results could lead to Phase III trials and eventual regulatory approval. The market for treatments for invasive pulmonary aspergillosis and lung transplant rejection is substantial, and successful commercialization of these drugs could generate significant revenue.
• Geographic Expansion: TFF Pharmaceuticals currently focuses on the United States and Australia. Expanding into other geographic markets, such as Europe and Asia, could drive further growth. These regions offer large patient populations and increasing healthcare spending. However, geographic expansion would require navigating different regulatory landscapes and establishing local partnerships.
• Development of Novel Formulations: TFF Pharmaceuticals can continue to innovate and develop novel formulations using its Thin Film Freezing (TFF) technology. This includes exploring new drug combinations, delivery methods, and targeting strategies. The company's ongoing research and development efforts could lead to the discovery of new drug candidates and applications for its technology.

What Are TFFP's Competitive Advantages?

• Patented Thin Film Freezing (TFF) technology provides a competitive advantage in drug formulation.
• Focus on inhaled dry powder drugs offers a differentiated approach to drug delivery.
• Clinical-stage pipeline with lead candidates in Phase II trials creates a barrier to entry.
• Strategic collaborations with universities and other companies enhance innovation and market reach.

What Does TFFP Do?

TFF Pharmaceuticals, Inc., founded in 2018 and based in Austin, Texas, is a clinical-stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. The company's core strategy revolves around creating inhaled dry powder formulations for the treatment of pulmonary diseases and conditions, offering a potentially more effective and convenient delivery method compared to traditional treatments. Their lead drug candidates include TFF Voriconazole Inhalation Powder, currently in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, also in Phase II clinical trials, aimed at preventing lung transplant rejection. Beyond these lead candidates, TFF Pharmaceuticals is also developing other dry powder products, including a cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain conditions. The company is also exploring Inhaled SARS-CoV2 Monoclonal Antibody for treating COVID-19 infections, Niclosamide Inhalation Powder for tapeworm infections and COVID-19, and various vaccines. TFF Pharmaceuticals collaborates with other entities, including a license agreement with the University of Texas at Austin for inhaled dry powder drug development, a joint development agreement with Augmenta Bioworks, Inc. for an inhaled SARS-CoV2 monoclonal antibody, and a licensing and collaboration agreement with UNION therapeutics A/S.

What Products and Services Does TFFP Offer?

• Develops inhaled dry powder drugs using Thin Film Freezing (TFF) technology.
• Focuses on treatments for pulmonary diseases and conditions.
• Conducts Phase II clinical trials for TFF Voriconazole Inhalation Powder (invasive pulmonary aspergillosis).
• Conducts Phase II clinical trials for TFF Tacrolimus Inhalation Powder (lung transplant rejection prevention).
• Develops cannabidiol substance for epilepsy, anxiety, insomnia, and pain.
• Explores Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 treatment.
• Develops Niclosamide Inhalation Powder for tapeworm infections and COVID-19.

How Does TFFP Make Money?

• Develops and patents drug formulations using its Thin Film Freezing (TFF) technology.
• Conducts clinical trials to demonstrate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved drugs through partnerships or direct sales.

What Industry Does TFFP Operate In?

TFF Pharmaceuticals operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for inhaled drug delivery systems is growing, driven by the increasing prevalence of respiratory diseases and the demand for more convenient and effective drug administration methods. TFF Pharmaceuticals' Thin Film Freezing (TFF) technology positions it to potentially capture a share of this market. Competitors include companies developing alternative drug delivery technologies and those focused on similar therapeutic areas.

Who Are TFFP's Key Customers?

• Patients suffering from pulmonary diseases and conditions.
• Hospitals and clinics that treat respiratory illnesses.
• Pharmaceutical companies seeking to license or acquire novel drug formulations.
• Transplant centers focused on preventing lung rejection.

Company Profile

TFF Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Harlan F. Weisman. TFFP has traded publicly since 2019.

TFF Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -34.60 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project TFF Pharmaceuticals, Inc. revenue of about $11.7M for fiscal 2026, with EPS near $-2.71.

The most recent 12 insider filings for TFF Pharmaceuticals, Inc. break down as 0 sales and 12 purchases. On net that is roughly 112K shares acquired (about $101K) — insiders putting money in tends to read as conviction.

TFFP Financials

TFFP Latest News

Common Questions About TFFP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources